The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Transforming growth factor β as a therapeutic target in systemic sclerosis
Open accessAbstract
Transforming growth factor β (TGF-β) is a pleiotropic cytokine with vital homeostatic functions. Aberrant TGF-β expression is implicated in the pathogenesis of fibrosis in systemic sclerosis (SSc); thus, TGF-β represents a molecular therapeutic target in this disease. Anti-TGF-β monoclonal antibody has been evaluated in a small trial of early SSc, with disappointing results. Antibodies against the αvβ6 integrin that prevent latent TGF-β activation, however, have shown promise in preclinical studies. Small-molecule inhibitors of TGF-β-receptor activity are effective in animal models of fibrosis. Imatinib mesylate and related tyrosine kinase inhibitors also block TGF-β pathways and abrogate fibrotic responses. The blocking of TGF-β activity might lead to spontaneous immune activation, epithelial hyperplasia and impaired wound healing. Loss of immune tolerance is a potential concern in an autoimmune disease such as SSc. Novel insights from microarray-based gene expression analyses and studies of genetic polymorphisms in TGF-β signaling could aid in identifying patients who are most likely to respond to anti-TGF-β treatment. This intervention promises to have a major impact on the treatment of SSc. Concerns regarding efficacy and safety and whether biomarkers can indicate these features, questions regarding appropriate dosing and timing of therapy, and identification of potential responders are critical challenges ahead.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Smad-dependent and Smad-independent pathways in TGF-β family signalling
Derynck, R., & Zhang, Y. E. (2003) · Nature · doi:10.1038/nature02006 · Cited by 5,373
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Role of Transforming Growth Factor β in Human Disease
Blobe, G. C., Schiemann, W. P., & Lodish, H. F. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005043421807 · Cited by 2,427
Munger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
SPECIFICITY AND VERSATILITY IN TGF-β SIGNALING THROUGH SMADS
Feng, X.-H., & Derynck, R. (2005) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.21.022404.142018 · Cited by 1,869
Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome
Habashi, J. P., Judge, D. P., Holm, T. M., Cohn, R. D., Loeys, B. L., Cooper, T. K., Myers, L., Klein, E. C., Liu, G., Calvi, C., et al. (2006) · Science · doi:10.1126/science.1124287 · Cited by 1,794
Making sense of latent TGFβ activation
Annes, J. P., Munger, J. S., & Rifkin, D. B. (2003) · Journal of Cell Science · doi:10.1242/jcs.00229 · Cited by 1,628
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387
Systemic sclerosis: a prototypic multisystem fibrotic disorder
Varga, J., & Abraham, D. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31139 · Cited by 1,163
Self-citationDistinct endocytic pathways regulate TGF-β receptor signalling and turnover
Di Guglielmo, G. M., Le Roy, C., Goodfellow, A. F., & Wrana, J. L. (2003) · Nature Cell Biology · doi:10.1038/ncb975 · Cited by 1,151
Reversal of experimental pulmonary hypertension by PDGF inhibition
Schermuly, R. T. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24838 · Cited by 1,058
Ziyadeh, F. N., Hoffman, B. B., Han, D. C., Iglesias-de la Cruz, M. C., Hong, S. W., Isono, M., Chen, S., McGowan, T. A., & Sharma, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120055097 · Cited by 907
Cohn, R. D., van Erp, C., Habashi, J. P., Soleimani, A. A., Klein, E. C., Lisi, M. T., Gamradt, M., ap Rhys, C. M., Holm, T. M., Loeys, B. L., et al. (2007) · Nature Medicine · doi:10.1038/nm1536 · Cited by 669
Role of transforming growth factor-β superfamily signaling pathways in human disease
Gordon, K. J., & Blobe, G. C. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.01.006 · Cited by 641
Daniels, C. E., Wilkes, M. C., Edens, M., Kottom, T. J., Murphy, S. J., LIMPER, A. H., & Leof, E. B. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19603 · Cited by 574
Imatinib for the Treatment of Pulmonary Arterial Hypertension
Ghofrani, H. A., Seeger, W., & Grimminger, F. (2005) · New England Journal of Medicine · doi:10.1056/nejmc051946 · Cited by 492
PPM1A Functions as a Smad Phosphatase to Terminate TGFβ Signaling
Lin, X., Duan, X., Liang, Y.-Y., Su, Y., Wrighton, K. H., Long, J., Hu, M., Davis, C. M., Wang, J., Brunicardi, F. C., et al. (2006) · Cell · doi:10.1016/j.cell.2006.03.044 · Cited by 485
Platelet-derived Growth Factor Expression and Function in Idiopathic Pulmonary Arterial Hypertension
Perros, F., Montani, D., Dorfmüller, P., Durand-Gasselin, I., Tcherakian, C., Le Pavec, J., Mazmanian, M., Fadel, E., Mussot, S., Mercier, O., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200707-1037oc · Cited by 472
Imatinib mesylate blocks a non‐Smad TGF‐β pathway and reduces renal fibrogenesis in vivo
Wang, S., Wilkes, M. C., Leof, E. B., & Hirschberg, R. (2005) · The FASEB Journal · doi:10.1096/fj.04-2370com · Cited by 463
Denton (2007) · doi:10.1002/art.22289 · Cited by 447
Partial Inhibition of Integrin αvβ6 Prevents Pulmonary Fibrosis without Exacerbating Inflammation
Horan, G. S., Wood, S., Ona, V., Li, D. J., Lukashev, M. E., Weinreb, P. H., Simon, K. J., Hahm, K., Allaire, N. E., Rinaldi, N. J., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-805oc · Cited by 420
Prud'homme, G. J. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700669 · Cited by 419
Kaminski, N., Allard, J. D., Pittet, J. F., Zuo, F., Griffiths, M. J. D., Morris, D., Huang, X., Sheppard, D., & Heller, R. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1778 · Cited by 417
Systemic and cell type-specific gene expression patterns in scleroderma skin
Whitfield, M. L., Finlay, D. R., Murray, J. I., Troyanskaya, O. G., Chi, J.-T., Pergamenschikov, A., McCalmont, T. H., Brown, P. O., Botstein, D., & Connolly, M. K. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1635114100 · Cited by 409
Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice
Nakao, A., Fujii, M., Matsumura, R., Kumano, K., Saito, Y., Miyazono, K., & Iwamoto, I. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6094 · Cited by 405
Yang, Y.-A., Dukhanina, O., Tang, B., Mamura, M., Letterio, J. J., MacGregor, J., Patel, S. C., Khozin, S., Liu, Z.-Y., Green, J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215333 · Cited by 404
Yang, Y.-A., Dukhanina, O. I., Tang, B., Mamura, M., Letterio, J. J., MacGregor, J., Patel, S. C., Khozin, S., Liu, Z.-Y., Green, J. D., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15333 · Cited by 404
Negative regulation of TGF-β receptor/Smad signal transduction
Itoh, S., & ten Dijke, P. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.02.015 · Cited by 388
Molecular Subsets in the Gene Expression Signatures of Scleroderma Skin
Milano, A., Pendergrass, S. A., Sargent, J. L., George, L. K., McCalmont, T. H., Connolly, M. K., & Whitfield, M. L. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002696 · Cited by 386
Distler, J. H. W., Jüngel, A., Huber, L. C., Schulze‐Horsel, U., Zwerina, J., Gay, R. E., Michel, B. A., Hauser, T., Schett, G., Gay, S., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22314 · Cited by 383
TGF‐β signaling: A tale of two responses
Rahimi, R. A., & Leof, E. B. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21501 · Cited by 371
Wang, Y., Fan, P., & Kahaleh, B. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21948 · Cited by 347
McCormick, L. L., Zhang, Y., Tootell, E., & Gilliam, A. C. (1999) · PubMed · Cited by 294
Puthawala, K., Hadjiangelis, N., Jacoby, S. C., Bayongan, E., Zhao, Z., Yang, Z., Devitt, M. L., Horan, G. S., Weinreb, P. H., Lukashev, M. E., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-806oc · Cited by 272
McCormick, L. L., Zhang, Y., Tootell, E., & Gilliam, A. C. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5693 · Cited by 265
Bonniaud, P., Margetts, P. J., Kolb, M., Schroeder, J. A., Kapoun, A. M., Damm, D., Murphy, A., Chakravarty, S., Dugar, S., Higgins, L., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-612oc · Cited by 256
Imatinib as a Novel Antifibrotic Agent in Bleomycin-induced Pulmonary Fibrosis in Mice
Aono, Y., Nishioka, Y., Inayama, M., Ugai, M., Kishi, J., Uehara, H., Izumi, K., & Sone, S. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-531oc · Cited by 231
Evaluation of Anti-TGF-β2 Antibody as a New Postoperative Anti-scarring Agent in Glaucoma Surgery
Mead, A. L., Wong, T. T. L., Cordeiro, M. F., Anderson, I. K., & Khaw, P. T. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-0978 · Cited by 225
Lin, F., Morrison, J. M., Wu, W., & Worman, H. J. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi040 · Cited by 218
Petersen, M., Thorikay, M., Deckers, M., van Dinther, M., Grygielko, E. T., Gellibert, F., de Gouville, A. C., Huet, S., ten Dijke, P., & Laping, N. J. (2008) · Kidney International · doi:10.1038/sj.ki.5002717 · Cited by 215
Milam, J. E., Keshamouni, V. G., Phan, S. H., Hu, B., Gangireddy, S. R., Hogaboam, C. M., Standiford, T. J., Thannickal, V. J., & Reddy, R. C. (2008) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00333.2007 · Cited by 211
Ghosh, A. K., Bhattacharyya, S., Lakos, G., Chen, S., Mori, Y., & Varga, J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20104 · Cited by 201
Self-citationSonnylal, S., Denton, C. P., Zheng, B., Keene, D. R., He, R., Adams, H. P., VanPelt, C. S., Geng, Y. J., Deng, J. M., Behringer, R. R., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22328 · Cited by 198
Moon, J.-A., Kim, H.-T., Cho, I.-S., Sheen, Y. Y., & Kim, D.-K. (2006) · Kidney International · doi:10.1038/sj.ki.5001775 · Cited by 197
Santiago, B., Gutierrez-Cañas, I., Dotor, J., Palao, G., Lasarte, J. J., Ruiz, J., Prieto, J., Borrás-Cuesta, F., & Pablos, J. L. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23859.x · Cited by 171
de Gouville, A., Boullay, V., Krysa, G., Pilot, J., Brusq, J., Loriolle, F., Gauthier, J., Papworth, S. A., Laroze, A., Gellibert, F., et al. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706172 · Cited by 166
Galdo, F. D., Sotgia, F., de Almeida, C. J., Jasmin, J., Musick, M., Lisanti, M. P., & Jiménez, S. A. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23791 · Cited by 165
Huber, L. C., Distler, J. H. W., Moritz, F., Hemmatazad, H., Hauser, T., Michel, B. A., Gay, R. E., Matucci‐Cerinic, M., Gay, S., Distler, O., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22759 · Cited by 165
Shi‐wen, X., Kennedy, L., Renzoni, E. A., Bou‐Gharios, G., du Bois, R. M., Black, C. M., Denton, C. P., Abraham, D. J., & Leask, A. (2007) · Arthritis & Rheumatism · doi:10.1002/art.23134 · Cited by 163
Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo
Tourkina, E., Richard, M., Göőz, P., Bonner, M., Pannu, J., Harley, R. A., Bernatchez, P. N., Sessa, W. C., Silver, R. M., & Hoffman, S. (2008) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00295.2007 · Cited by 157
Effect of rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2on bleomycin-induced lung injury
Genovese, T., Cuzzocrea, S., Paola, R. D., Mazzon, E., Mastruzzo, C., Catalano, P., Sortino, M. A., Crimi, N., Caputi, A. P., Thiemermann, C., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00049704 · Cited by 156
Weng, H., Mertens, P. R., Gressner, A. M., & Dooley, S. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2006.09.014 · Cited by 152
Hepatocyte Growth Factor Inhibits Epithelial to Myofibroblast Transition in Lung Cells via Smad7
Shukla, M. N., Rose, J. L., Ray, R., Lathrop, K. L., Ray, A., & Ray, P. (2008) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2008-0217oc · Cited by 149
Imatinib mesylate treatment of nephrogenic systemic fibrosis
Kay, J., & High, W. A. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23696 · Cited by 149
Imatinib Mesylate in the Treatment of Refractory Idiopathic Pulmonary Arterial Hypertension
Patterson, K. C., Weissmann, A., Ahmadi, T., & Farber, H. W. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-2-200607180-00020 · Cited by 148
Germline Allele-Specific Expression of TGFBR1 Confers an Increased Risk of Colorectal Cancer
Valle, L., Serena-Acedo, T., Liyanarachchi, S., Hampel, H., Comeras, I., Li, Z., Zeng, Q., Zhang, H.-T., Pennison, M. J., Sadim, M., et al. (2008) · Science · doi:10.1126/science.1159397 · Cited by 141
Self-citationScleroderma and Smads: Dysfunctional Smad family dynamics culminating in fibrosis
Varga, J. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10413 · Cited by 135
Self-citationSaxena, V., Lienesch, D. W., Zhou, M., Bommireddy, R., Azhar, M., Doetschman, T., & Singh, R. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.3.1903 · Cited by 120
Smad7 as a therapeutic agent for chronic kidney diseases
Lan, H. Y. (2008) · Frontiers in bioscience · doi:10.2741/3057 · Cited by 119
Molecular framework for response to imatinib mesylate in systemic sclerosis
Chung, L. S., Fiorentino, D. F., BenBarak, M. J., Adler, A. S., Mariano, M., Paniagua, R. T., Milano, A., Connolly, M. K., Ratiner, B. D., Wiskocil, R. L., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24221 · Cited by 116
Mori, Y., Ishida, W., Bhattacharyya, S., Li, Y., Platanias, L. C., & Varga, J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20658 · Cited by 111
Self-citationFukasawa, H., Yamamoto, T., Suzuki, H., Togawa, A., Ohashi, N., Fujigaki, Y., Uchida, C., Aoki, M., Hosono, M., Kitagawa, M., et al. (2003) · Kidney International · doi:10.1111/j.1523-1755.2004.00393.x · Cited by 106
Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate
Pannu, J., Asano, Y., Nakerakanti, S. S., Smith, E. A., Jabłońska, S., Błaszczyk, M., ten Dijke, P., & Trojanowska, M. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23698 · Cited by 94
Trichostatin A blocks TGF-β-induced collagen gene expression in skin fibroblasts: Involvement of Sp1
Ghosh, A. K., Mori, Y., Dowling, E., & Varga, J. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.12.204 · Cited by 91
Self-citationPlatten, M., Wild‐Bode, C., Wick, W., Leitlein, J., DICHGANS, J., & Weller, M. (2001) · International Journal of Cancer · doi:10.1002/ijc.1289 · Cited by 91
Ishida, W., Mori, Y., Lakos, G., Sun, L., Shan, F., Bowes, S., Josiah, S., Lee, W., Singh, J., Ling, L. E., et al. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700303 · Cited by 88
Self-citationFu, K., Corbley, M. J., Sun, L., Friedman, J. E., Shan, F., Papadatos, J. L., Costa, D. E., Lutterodt, F., Sweigard, H., Bowes, S., et al. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.158030 · Cited by 85
Zhao, B. M., & Hoffmann, F. M. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-10-0990 · Cited by 81
Scleroderma-like cutaneous lesions induced by paclitaxel: A case study
Kupfer, I., Balguérie, X., Courville, P., Chinet-Charrot, P., & Joly, P. (2003) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2003.30 · Cited by 77
Targeting transforming growth factor-β signaling
Pennison, M. J., & Pasche, B. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3282f0ad0e · Cited by 71
Self-citationImatinib for the treatment of refractory, diffuse systemic sclerosis
Sfikakis, P. P., Gorgoulis, V. G., Katsiari, C. G., Evangelou, K., Kostopoulos, C., & Black, C. M. (2008) · Rheumatology · doi:10.1093/rheumatology/ken104 · Cited by 68
Fietta, A., Bardoni, A., Salvini, R., Passadore, I., Morosini, M., Cavagna, L., Codullo, V., Pozzi, E., Meloni, F., & Montecucco, C. (2006) · Arthritis Research & Therapy · doi:10.1186/ar2067 · Cited by 66
Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD
Magro, L., Catteau, B., Coiteux, V., Bruno, B., Jouet, J. P., & Yakoub‐Agha, I. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.252 · Cited by 62
Tgfbr1 Haploinsufficiency Is a Potent Modifier of Colorectal Cancer Development
Zeng, Q., Phukan, S., Xu, Y., Sadim, M. S., Rosman, D. S., Pennison, M. J., Liao, J., Yang, G.-Y., Huang, C., Valle, L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3980 · Cited by 61
Self-citationVittal, R., Zhang, H., Han, M. K., Moore, B. B., Horowitz, J. C., & Thannickal, V. J. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.113407 · Cited by 59
Sabnani, I., Zucker, M. J., Rosenstein, E. D., Baran, D. A., Arroyo, L. H., Tsang, P., Zubair, M., & Rivera, V. (2008) · Lara D. Veeken · doi:10.1093/rheumatology/ken369 · Cited by 59
The Antifibrogenic Potential of PPARγ Ligands in Pulmonary Fibrosis
Sime, P. J. (2008) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e31816464e9 · Cited by 55
Role of α1-Acid Glycoprotein in Therapeutic Antifibrotic Effects of Imatinib with Macrolides in Mice
Azuma, M., Nishioka, Y., Aono, Y., Inayama, M., Makino, H., Kishi, J., Shono, M., Kinoshita, K., Uehara, H., Ogushi, F., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200702-178oc · Cited by 53
Ruzek, M. C., Hawes, M. L., Pratt, B. M., McPherson, J. M., Ledbetter, S., Richards, S. M., & Garman, R. D. (2003) · Immunopharmacology and Immunotoxicology · doi:10.1081/iph-120020473 · Cited by 52
Is imatinib mesylate a promising drug in systemic sclerosis?
van Daele, P. L. A., Dik, W. A., Thio, H. B., van Hal, P. T. W., van Laar, J. A. M., Hooijkaas, H., & van Hagen, P. M. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23648 · Cited by 50
The Effect of Imatinib (Glivec®) on Scleroderma and Normal Dermal Fibroblasts: A Preclinical Study
Soria, A., Cario, M., Lepreux, S., Rezvani, H. R., Pasquet, J., Pain, C., Schaeverbeke, T., Mahon, F., & Taı̈eb, A. (2008) · Dermatology · doi:10.1159/000111507 · Cited by 48
Imatinib as a Potential Treatment for Sclerodermatous Chronic Graft-vs-Host Disease
Moreno-Romero, J. A. (2008) · Archives of Dermatology · doi:10.1001/archderm.144.9.1106 · Cited by 35
In perspective: Murine models of scleroderma
Wu, M., & Varga, J. (2008) · Current Rheumatology Reports · doi:10.1007/s11926-008-0030-9 · Cited by 31
Self-citationYamada, H. (1995) · Journal of Dermatological Science · doi:10.1016/0923-1811(94)00355-i · Cited by 31
Rosenbloom, J., & Jiménez, S. A. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23634 · Cited by 30
Endothelin and scleroderma lung disease
Silver, R. M. (2008) · Rheumatology · doi:10.1093/rheumatology/ken283 · Cited by 28
Cited by
Recent Developments in Myofibroblast Biology
Hinz, B., Phan, S. H., Thannickal, V. J., Prunotto, M., Desmoulière, A., Varga, J., De Wever, O., Mareel, M., & Gabbiani, G. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.02.004 · Cited by 1,193
Self-citationBiernacka, A., Dobaczewski, M., & Frangogiannis, N. G. (2011) · Growth Factors · doi:10.3109/08977194.2011.595714 · Cited by 1,161
Allanore, Y., Simms, R., Distler, O., Trojanowska, M., Pope, J., Denton, C. P., & Varga, J. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.2 · Cited by 876
Self-citationRole of EMT in Metastasis and Therapy Resistance
Smith, B., & Bhowmick, N. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5020017 · Cited by 484
TGF-β1 – A truly transforming growth factor in fibrosis and immunity
Lodyga, M., & Hinz, B. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.12.010 · Cited by 458
Metadata
- Authors
- Varga, J., & Pasche, B.
- Venue
- Nature Reviews Rheumatology
- Published
- 2009-04
- Volume
- 5
- Issue
- 4
- Pages
- 200-206
- ISSN
- 1759-4790 (ISSN-L)
- 1759-4804
- OpenAlex
- W2063099598
- Cited by
- 295
- References
- 87
- FWCI
- 2.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.